Immunotoxic response can originate from direct toxicity of the pharmaceutical to components of the immune system. Direct immunotoxicity may result in either immunosuppression or immunostimulation. Alternatively, the immune system may react to chemicals in an antigen-specific way. Therefore, immunotoxicology is an important aspect of the safety evaluation of drugs and chemicals. Despite the remarkable success of rodent-based models in determining immunotoxicity, there are limitations in extrapolating the risk posed to humans. Immunotoxicological data resources derived from studies using human primary leukocytes can facilitate rational decision making for drug development.
Amerigo Scientific offers Skimune® Immunotoxicity Testing, which can be used as a "first in human study" for safety and efficacy testing of drugs, chemicals, or cosmetics. This in vitro test could serve as an alternative to animal models.
Based on Skimune® Immunotoxicity Testing platform, it is possible to predict the adverse immune response triggered by the tested compound, demonstrating whether the compound has the potential to activate the human immune system by analyzing dendritic cells/T cells activation, cytokine release and histopathology associated with allergy, hypersensitivity, or sensitization.
Note: If you don't receive our verification email, do the following: